TS-1 combination OD tablet specific use-results survey "To evaluate safety of tegafur, gimeracil, oteracil potassium combination OD tablet"

Trial Profile

TS-1 combination OD tablet specific use-results survey "To evaluate safety of tegafur, gimeracil, oteracil potassium combination OD tablet"

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Feb 2017

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary)
  • Indications Gastric cancer
  • Focus Adverse reactions
  • Sponsors Taiho Pharmaceutical Company
  • Most Recent Events

    • 12 Aug 2016 Status changed from recruiting to active, no longer recruiting.
    • 10 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top